|
去甲基柔红霉素联合阿糖胞苷治疗急性非淋巴细胞性白血病疗效观察 |
|
为IA可作为ANLL的首选化疗方案,对复发及难治性病例因IDA与其他蒽环类药物无交叉耐药性,故IA方案有可能为他们提供再次获得缓解的机会。
作者单位:710032 西安,第四军医大学西京医院血液内科
参考文献
1 Berman E. New drugs in acute myelogenous leukemia: a review. J Clin Pharmacol, 1992,32:296-309. 2 Carella AM, Pungolino E, Piatti G, et al. Idarubicin in combination with inte mediate-dose cytarabine in the treatment of refractrry or relapsed acute leukemia. Eur J Haematol, 1989,43:309-313. 3 Wiernik PH, Case DC Jr, Periman PO, et al. A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia. Semin Oncol, 1989, 16(1 Suppl 2):25-29. 4 Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenons leukemia. Blood, 1991,77:1666-1674.
上一页 [1] [2] 上一个医学论文: 体外循环术中心肌缺血 下一个医学论文: 葛根素对急性缺血再灌流损伤肾脏的保护作用
|
|
|